Oncology therapies

Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, is developing poziotinib in non-small cell lung cancer (NSCLC) EGFR exon 20 mutations and beyond. New clinical data from the poziotinib Phase 2 investigator-initiated trial in NSCLC EGFR exon 20 mutations, conducted by the University of Texas MD Anderson Cancer Center will be presented during the IASLC 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer taking place in Barcelona, Spain from September 7-10, 2019. “There continues to be investigator interest in poziotinib’s unique characteristics to address NSCLC mutations, including exon 20 and other mutations, which have limited or no treatment options,” said Francois Lebel, M.D., F.R.C.P.C., Chief Medical Officer of Spectrum Pharmaceuticals. “The data presented at this conference by our scientific collaborators at MD Anderson further expands the body of evidence supporting poziotinib’s role in lung cancer and helps us gain new insights into its full potential.”